FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2124707313> ?p ?o ?g. }

• W2124707313 endingPage "3286" @default.
• W2124707313 startingPage "3279" @default.
• W2124707313 abstract "Are self-reported menstrual disorders associated with hyperandrogenaemia and metabolic disturbances as early as in adolescence?Menstrual disorders at the age 16 are a good marker of hyperandrogenaemia, and an adverse lipid profile was associated with higher androgen levels.Hyperandrogenism per se has been suggested to be a significant metabolic risk factor in women and a cause of physical and psychological morbidity in adolescent girls. A weak positive correlation has been described between hyperandrogenaemia and obesity in adolescent girls, but the clinical consequences are still poorly understood. Hyperandrogenism and insulin resistance are also key features of polycystic ovary syndrome (PCOS), and women with PCOS are consequently at an increased risk of developing type 2 diabetes mellitus and/or metabolic syndrome, and may have increased cardiovascular morbidity. Our findings confirm that the association between menstrual disorders, hyperandrogenism, obesity and metabolic risks is already evident in adolescence.This population-based, cross-sectional study used postal questionnaires to targeting 15-16-year-old girls in the Northern Finland Birth Cohort 1986 (n= 4567).There were 3669 girls who answered the postal questionnaire and out of 3373 girls who also underwent clinical examinations and blood tests, 2448 were included in the analyses. The questionnaire included one question about the regularity and length of the menstrual cycle: 'Is your menstrual cycle (the interval from the beginning of one menstrual period to the beginning of the next period) often (more than twice a year) longer than 35 days?' The girls who answered 'yes' to this question were considered to be suffering from menstrual disorders and were classified as 'symptomatic'. The girls who answered 'no' were defined as 'non-symptomatic'.There were 709 (29%) girls who reported menstrual disorders (symptomatic girls) and 1739 who had regular periods (non-symptomatic girls). In the whole population and in both study groups, there were significant correlations between body mass index (BMI) (and waist-to-hip ratio), hyperandrogenaemia and metabolic parameters. Symptomatic girls exhibited significantly higher serum concentrations of testosterone (P= 0.010), lower levels of sex hormone-binding globulin (P =0.042) and higher free androgen indices [FAIs; geometric mean 3.38 (interquartile range (IQR): 2.27, 5.18) versus 3.08 (IQR: 2.15, 4.74), P= 0.002]. The two groups had comparable BMI and insulin sensitivity, and serum levels of glucose, insulin and lipids. There was a significant linear trend towards higher FAI values in the higher BMI quartiles in both symptomatic and non-symptomatic girls. In the whole population, there was a statistically significant linear decrease in high-density lipoprotein concentrations (P < 0.001) and higher triglyceride concentrations (P =0.004) in the upper FAI quartile.Information regarding menstrual disorders in adolescence is a good marker of hyperandrogenaemia and may be an early risk factor for the development of PCOS in adulthood. The association between obesity, hyperandrogenism and metabolic risks is already evident in adolescence, which strengthens the importance of noting menstrual disorders at an early stage. BIAS, LIMITATIONS, GENERALIZABILITY: The cross-sectional nature of the study does not allow us to draw conclusions concerning the metabolic risks of this population in later life. The diagnosis of menstrual disorders was based on a questionnaire, suggesting a risk of information bias in reporting the symptoms. This study was not designed to diagnose PCOS, as ultrasonography was not available and there was no clinical evaluation of hyperandrogenism (i.e. hirsutism). However, we were able to take into account potential confounding factors in the analyses.This work was supported by grants from the Finnish Medical Society Duodecim, the North Ostrobothnia Regional Fund, the Academy of Finland (project grants 104781, 120315, 129269, 1114194, SALVE), University Hospital Oulu, Biocenter, University of Oulu, Finland (75617), the European Commission (EURO-BLCS, Framework 5 award QLG1-CT-2000-01643) and the Medical Research Council, UK (PrevMetSyn/SALVE). None of the authors have any conflict of interest to declare." @default.
• W2124707313 created "2016-06-24" @default.
• W2124707313 creator A5011779920 @default.
• W2124707313 creator A5018096102 @default.
• W2124707313 creator A5032357089 @default.
• W2124707313 creator A5049484171 @default.
• W2124707313 creator A5059746849 @default.
• W2124707313 creator A5065880873 @default.
• W2124707313 creator A5068508022 @default.
• W2124707313 creator A5072892800 @default.
• W2124707313 creator A5084192967 @default.
• W2124707313 creator A5085407302 @default.
• W2124707313 creator A5089464396 @default.
• W2124707313 creator A5091356737 @default.
• W2124707313 date "2012-08-29" @default.
• W2124707313 modified "2023-10-06" @default.
• W2124707313 title "Menstrual disorders in adolescence: a marker for hyperandrogenaemia and increased metabolic risks in later life? Finnish general population-based birth cohort study" @default.
• W2124707313 cites W1965402814 @default.
• W2124707313 cites W1969062482 @default.
• W2124707313 cites W1994522591 @default.
• W2124707313 cites W2000075793 @default.
• W2124707313 cites W2004708554 @default.
• W2124707313 cites W2015476724 @default.
• W2124707313 cites W2030617780 @default.
• W2124707313 cites W2035414092 @default.
• W2124707313 cites W2053682781 @default.
• W2124707313 cites W2055323349 @default.
• W2124707313 cites W2059854329 @default.
• W2124707313 cites W2060135729 @default.
• W2124707313 cites W2089589494 @default.
• W2124707313 cites W2091933058 @default.
• W2124707313 cites W2095810284 @default.
• W2124707313 cites W2100610283 @default.
• W2124707313 cites W2105749473 @default.
• W2124707313 cites W2119399665 @default.
• W2124707313 cites W2128317410 @default.
• W2124707313 cites W2135851189 @default.
• W2124707313 cites W2144997397 @default.
• W2124707313 cites W2145217304 @default.
• W2124707313 cites W2157068724 @default.
• W2124707313 cites W2165743275 @default.
• W2124707313 cites W4229769865 @default.
• W2124707313 cites W4242321355 @default.
• W2124707313 cites W4248430388 @default.
• W2124707313 cites W4250446958 @default.
• W2124707313 cites W4250748828 @default.
• W2124707313 doi "https://doi.org/10.1093/humrep/des309" @default.
• W2124707313 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22933528" @default.
• W2124707313 hasPublicationYear "2012" @default.
• W2124707313 type Work @default.
• W2124707313 sameAs 2124707313 @default.
• W2124707313 citedByCount "43" @default.
• W2124707313 countsByYear W21247073132012 @default.
• W2124707313 countsByYear W21247073132013 @default.
• W2124707313 countsByYear W21247073132014 @default.
• W2124707313 countsByYear W21247073132015 @default.
• W2124707313 countsByYear W21247073132016 @default.
• W2124707313 countsByYear W21247073132017 @default.
• W2124707313 countsByYear W21247073132018 @default.
• W2124707313 countsByYear W21247073132019 @default.
• W2124707313 countsByYear W21247073132020 @default.
• W2124707313 countsByYear W21247073132021 @default.
• W2124707313 countsByYear W21247073132022 @default.
• W2124707313 countsByYear W21247073132023 @default.
• W2124707313 crossrefType "journal-article" @default.
• W2124707313 hasAuthorship W2124707313A5011779920 @default.
• W2124707313 hasAuthorship W2124707313A5018096102 @default.
• W2124707313 hasAuthorship W2124707313A5032357089 @default.
• W2124707313 hasAuthorship W2124707313A5049484171 @default.
• W2124707313 hasAuthorship W2124707313A5059746849 @default.
• W2124707313 hasAuthorship W2124707313A5065880873 @default.
• W2124707313 hasAuthorship W2124707313A5068508022 @default.
• W2124707313 hasAuthorship W2124707313A5072892800 @default.
• W2124707313 hasAuthorship W2124707313A5084192967 @default.
• W2124707313 hasAuthorship W2124707313A5085407302 @default.
• W2124707313 hasAuthorship W2124707313A5089464396 @default.
• W2124707313 hasAuthorship W2124707313A5091356737 @default.
• W2124707313 hasBestOaLocation W21247073131 @default.
• W2124707313 hasConcept C126322002 @default.
• W2124707313 hasConcept C131872663 @default.
• W2124707313 hasConcept C134018914 @default.
• W2124707313 hasConcept C142052008 @default.
• W2124707313 hasConcept C142724271 @default.
• W2124707313 hasConcept C187212893 @default.
• W2124707313 hasConcept C201903717 @default.
• W2124707313 hasConcept C2777391703 @default.
• W2124707313 hasConcept C2779058012 @default.
• W2124707313 hasConcept C2779771394 @default.
• W2124707313 hasConcept C2780186808 @default.
• W2124707313 hasConcept C2780578515 @default.
• W2124707313 hasConcept C2908647359 @default.
• W2124707313 hasConcept C29456083 @default.
• W2124707313 hasConcept C3018442814 @default.
• W2124707313 hasConcept C511355011 @default.
• W2124707313 hasConcept C71315377 @default.
• W2124707313 hasConcept C71924100 @default.
• W2124707313 hasConcept C72563966 @default.
• W2124707313 hasConcept C99454951 @default.

• next